Live GMAT classes with Target Test Prep start Nov 21 and Nov 22. First class free.

See classes
Target Test Prep · GMAT

Choose how you want to prepare

Learn live with an expert or move at your own pace. Every option includes the complete TTP study system.

Newsweek Readers’ Choice Awards 2026 winner: Target Test Prep, #1 Test Prep

Target Test Prep was voted #1 Best Test Prep in the 2026 Newsweek Readers’ Choice™ Awards.

★★★★★5.0563 reviews
GMATLiveTeachStarts Nov 22
Josh Braslow, Target Test Prep GMAT expert
LIVE ONLINE CLASSES

Get Ready for GMAT Test Day Faster with Live Online Classes

with Josh Braslow, 20+ years in test prep

Nov 22 · Josh Braslow
Sun · 9:30 AM to 12:30 PM ET
Included
40 hours of live online classes + 6 months of TTP OnDemand
  • Attend the first class for free
  • Every class is recorded, so you never fall behind
View classes & enroll
Limited seats availableTarget Test Prep
EALiveTeachOnDemandStart anytime
EXECUTIVE ASSESSMENT

Target Test Prep EA OnDemand

Self-paced EA prep. Study on your schedule.

EXECUTIVE ASSESSMENT

with

165+ EA score guarantee
$05-day trial no automatic billing
Schedule
Included
40 hours of live online classes plus six months of access to the complete TTP EA OnDemand course.
  • 165+ EA Score Guarantee
  • 4,100+ Quant, Verbal, and Integrated Reasoning practice questions
  • 400+ hours of in-depth video lessons
  • 3,000+ step-by-step video solutions
View EA class & enroll Start free 5-day trial
Limited cohort · enrollment openTrial includes full course accessTarget Test Prep
GMATOnDemandStart anytime
SELF-PACED MASTERCLASS

Target Test Prep GMAT OnDemand

Complete access from day one. Study on your schedule.

715+ score guarantee
$0to start then $127/mo
  • Personalized study plan and analytics
  • Thousands of lessons and practice questions
Start free 5-day trial
Read 563 reviewsTarget Test Prep

The new drug Prozac and the old one Elavil are about

Expert replies
Post new topic Post Reply
Subscribe topic
Previous Topic Next Topic
Moderator
Posts: 7187
Joined: Thu Sep 07, 2017 4:43 pmFollowed by: 23 members
by BTGmoderatorDC » Sun May 27, 2018 12:18 am
Timer
00:00
Your answer
Difficulty–

right wrong

Pick an answer to see how members did

The new drug Prozac and the old one Elavil are about equally effective in treating various forms of depression, although patients on the newer drug may have slightly fewer side effects. Thus, revenue from the sale of the new drug is going to far exceed the revenue from the sale of the old drug.

All of the following statements weaken the conclusion of the argument above, EXCEPT:

(A) Elavil is also used as a powerful anti-emetic medicine.

(B) The Drug Control Authorities in six states have refused to allow the sale of Prozac till some more tests are carried out.

(C) Some side effects of Elavil are common to Prozac as well.

(D) Prozac is not recommended as an anti-depressant for diabetics and heart patients.

(E) The unit sale price of Elavil is higher than that of Prozac.
Top
Join the discussion
Source: — Critical Reasoning |
Legendary Member
Posts: 2214
Joined: Fri Mar 02, 2018 2:22 pmFollowed by: 5 members

by deloitte247 » Wed Jun 27, 2018 11:50 am
Option A - CORRECT.
This option is almost appropriate among other options stated below. Elavil is also a strong medication used in treating various forms of depression except that its side effect is stronger than the newer drug and has reduced the rate at which it is recommended.

Option B - INCORRECT.
This statement is not proven in the researchers study stated, so therefor it is wrong.

Option C - CORRECT.
This statement is right because, according to the researcher they both have similar side effect only that Prozac as the newer one has slightly fewer side effect compared to the Elavil.

Option D - INCORRECT.
This statement may be part of the study conducted by the researcher but was not stated in the question which makes it invalid.

Option E - INCORRECT.
This option is incorrect because, it is stated in the study that the unit sale of Prozac is higher than that of Elavil.
Top
Join the discussion